News 04
For Immediate Release: July 17, 2001
Contact: Suzanne Shelton (847) 676-4337
SuzanneSheltonPR@aol.com
Science Behind ForsLean® Garners Best New Dietary Supplement Product Of The Year Award For Sabinsa
PISCATAWAY, NJ – Each year, the leading science minds in the nutraceuticals industry gather at the Nutracon conference to learn about new dietary supplement research and innovations. One of the highlights of the conference is the annual presentation of the NutraAward, where the attendees vote for the best new product based upon its scientific merits. Sabinsa was proud and pleased to the chosen by some of the most respected people in nutraceutical science as having the best new product of the year, ForsLean®, at Nutracon in San Diego last week.
"To be honored with this award by our peers from the scientific, academic and business communities is significant," stated Mark C. Sysler, Sr. Executive Vice President, Sabinsa Corporation. "To have such a diverse, well informed group give us this recognition after reviewing the body of evidence we've developed over the past four years confirms our belief that Sabinsa really does have a winner in ForsLean®."
ForsLean® is a proprietary ingredient that has been patented for its use in promoting lean body mass. The ingredient's weight management properties are a recent discovery, which is not a traditional usage of the herb from which it is derived. Sabinsa was granted U.S. Patent #5,804,596 for its use and composition in promotion of lean body mass, reduction of adipose tissue (fat) and weight loss. Dietary supplements containing ForsLean® will have it listed by name on the label.
"ForsLean® shifts the proportion between lean body mass and adipose, or fatty, tissue in favor of lean body mass, which improves overall health," explains Vladimir Badmaev, MD, PhD, Sabinsa Corporation’s Vice President, Scientific and Medical Affairs. "The effect can be measured by decreases in the waist hip ratio and the body mass index."
ForsLean® has been tested by independent laboratories in the U.S. for safety and toxicity (LD50 and AMES tests, respectively). At the dosage used in preliminary clinical trials, patients experienced no adverse side effects. Two additional clinical studies using ForsLean® are now underway in the U.S. and in Japan.
Voting criteria included:
- Scientific Merit
- Efficacy
- Safety
- Innovation
- Market Potential
- Does it advance the credibility of our industry?
For more information please check the ForsLean® web site at www.forslean.com, or www.forslean.net. Contact Sabinsa at either their New Jersey office (732-777-1111) or their Utah office (801-465-8400).
ForsLean® is a registered trademark of the Sabinsa Corporation.
